BioSpace News Archive

Drug Development

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase III Trial for Chronic Migraine Prevention

The primary endpoint met: reduction of 8.2 monthly migraine days from baseline compared to 5.6 days for placebo.

January 8, 2018
·
12 min read
Alimera Sciences Refinances Debt With New $40M Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth.

January 8, 2018
·
5 min read
Business

Cypralis and Gilead Agree on License Terms Under Which Cypralis Will Hold Exclusive Development and Commercialization Rights to Certain Jointly-Owned ‘Cyprolides’ for Acute and Chronic Degenerative Diseases

Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology.

January 8, 2018
·
1 min read
Business

Sanifit Announces the Appointment of Cris Calsada as CFO

Ms. Calsada joins Sanifit with over 20 years of corporate finance and executive experience in the life sciences and technology industries.

January 8, 2018
·
2 min read
Business

Profound Medical Corp. Announces Preliminary Fourth Quarter 2017 Revenue and Provides Progress Update on TACT Pivotal Trial Patient Enrollment

Profound anticipates total revenues for the fourth quarter of 2017 to be approximately $1.9 million.

January 8, 2018
·
5 min read
Biotech Beach

AntiCancer Inc. Has Developed a Methuselah Enzyme Taken Orally That Hopefully Extends Normal Lifespan and Also Arrests Cancer

The common amino-acid methionine, present in all proteins, is a culprit in the aging process as well as in cancer.

January 8, 2018
·
2 min read
BioMidwest

KemPharm Initiates Pivotal Efficacy Trial of KP415

The trial is designed to support a potential label for KP415 for both an early onset and long duration of a KP415 treatment effect in ADHD patients.

January 8, 2018
·
5 min read
Drug Development

CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients With Primary Biliary Cholangitis

The objectives of the study are to provide additional long-term safety and efficacy data that will support the seladelpar registration program and to follow patients until registration of seladelpar.

January 8, 2018
·
5 min read
Genetown

Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals

The Company will provide further details during its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2018 at 4:00 pm PT.

January 8, 2018
·
6 min read
Business

OCuSOFT Partners With I-MED Pharma to Bring the I-PEN Osmolarity System to the U.S.

This distribution partnership will officially commence upon final FDA approval of the 510k, which is anticipated in the first quarter of 2018.

January 8, 2018
·
4 min read